These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8925844)

  • 1. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R; McKillop JH; Pearson DW; Cuthbert GF; Thomson JA
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PREDICTION OF RELAPSE FROM HYPERTHYROIDISM FOLLOWING ANTITHYROID MEDICATION WITHDRAWAL USING TECHNETIUM THYROID UPTAKE SCANNING.
    Nakhjavani M; Abdollahi S; Farzanefar S; Abousaidi M; Esteghamati A; Naseri M; Eftekhari M; Abbasi M
    Endocr Pract; 2017 Apr; 23(4):466-470. PubMed ID: 28437154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
    Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
    J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume.
    Pfeilschifter J; Ziegler R
    Eur J Endocrinol; 1997 Jan; 136(1):81-6. PubMed ID: 9037131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
    Grebe SK; Feek CM; Ford HC; Fagerström JN; Cordwell DP; Delahunt JW; Toomath RJ
    Clin Endocrinol (Oxf); 1998 May; 48(5):585-92. PubMed ID: 9666870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
    Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
    Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid function and immunological activity during and after medical treatment of Graves' disease.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    Clin Endocrinol (Oxf); 1983 Jul; 19(1):87-96. PubMed ID: 6137296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
    García-Mayor RV; Páramo C; Luna Cano R; Pérez Mendez LF; Galofré JC; Andrade A
    J Endocrinol Invest; 1992 Dec; 15(11):815-20. PubMed ID: 1283984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prediction of remission in Graves' disease after thionamide therapy by technetium-99m early uptake].
    Misaki T; Dokoh S; Koh T; Shimbo S; Hidaka A; Iida Y; Kasagi K; Konishi J
    Kaku Igaku; 1991 Feb; 28(2):157-61. PubMed ID: 1711131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of primary hyperthyroidism caused by Graves' disease admixed with resistance to thyroid hormone (P453T).
    Sato H
    Endocr J; 2010; 57(8):687-92. PubMed ID: 20574139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year.
    Talbot JN; Duron F; Féron R; Aubert P; Milhaud G
    J Endocrinol Invest; 1989 Oct; 12(9):589-95. PubMed ID: 2573625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.